A Novel Bone Anabolic Treatment in a Mouse Model of Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a heritable disorder that causes bone fractures. The drugs that are used at present help to decrease the number of fractures by about half, but most people with OI have many fractures despite receiving currently available treatments. Mesentech Inc has developed a new drug that has shown a strong effect on bone formation in rats. In this project, we will test the effect of this drug in a mouse model of OI. The new drug will be injected three times per week during a period of four weeks and the effect on bone strength will be assessed. We expect that the new drug will increase bone formation activity and make bones stronger in OI mice. This will open a potential new treatment avenue for patients with OI.

Intern: 
Boraschi Diaz
Faculty Supervisor: 
Frank Rauch
Province: 
Quebec
University: 
Partner: 
Partner University: 
Discipline: 
Program: